CARDIO-NOTES
Open in Telegram
📈 Analytical overview of Telegram channel CARDIO-NOTES
Channel CARDIO-NOTES (@cardionotesposts) in the Arabic language segment is an active participant. Currently, the community unites 11 427 subscribers, ranking 2 368 in the Medicine category and 2 311 in the Egypt region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 11 427 subscribers.
According to the latest data from 25 August, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 149 over the last 30 days and by 9 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 9.74%. Within the first 24 hours after publication, content typically collects N/A% reactions from the total number of subscribers.
- Post reach: On average, each post receives 0 views. Within the first day, a publication typically gains 0 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 0.
- Thematic interests: Content is focused on key topics such as مَرِيض, ضَغط, عِلَاج, حَالَة, جُرعَة.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“قناة خاصة بمنشورات طوارئ وعيادة القلب”
Thanks to the high frequency of updates (latest data received on 26 August, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
11 427
Subscribers
+924 hours
+357 days
+14930 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
August '26
August '26
+160
in 0 channels
July '26
+40
in 0 channels
Get PRO
June '26
+215
in 0 channels
Get PRO
May '26
+2 062
in 0 channels
Get PRO
April '26
+68
in 0 channels
Get PRO
March '26
+1 394
in 1 channels
Get PRO
February '26
+520
in 1 channels
Get PRO
January '26
+666
in 3 channels
Get PRO
December '25
+144
in 0 channels
Get PRO
November '25
+349
in 0 channels
Get PRO
October '25
+112
in 1 channels
Get PRO
September '25
+140
in 2 channels
Get PRO
August '25
+624
in 5 channels
Get PRO
July '25
+336
in 3 channels
Get PRO
June '25
+632
in 2 channels
Get PRO
May '25
+436
in 0 channels
Get PRO
April '25
+314
in 1 channels
Get PRO
March '25
+681
in 1 channels
Get PRO
February '25
+221
in 2 channels
Get PRO
January '25
+636
in 2 channels
Get PRO
December '24
+274
in 0 channels
Get PRO
November '24
+552
in 0 channels
Get PRO
October '24
+66
in 0 channels
Get PRO
September '24
+1 152
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 26 August | +5 | |||
| 25 August | +9 | |||
| 24 August | 0 | |||
| 23 August | +17 | |||
| 22 August | +1 | |||
| 21 August | +4 | |||
| 20 August | +4 | |||
| 19 August | +2 | |||
| 18 August | 0 | |||
| 17 August | +1 | |||
| 16 August | +2 | |||
| 15 August | +1 | |||
| 14 August | +3 | |||
| 13 August | +4 | |||
| 12 August | +5 | |||
| 11 August | +1 | |||
| 10 August | +4 | |||
| 09 August | 0 | |||
| 08 August | +5 | |||
| 07 August | +3 | |||
| 06 August | +6 | |||
| 05 August | +16 | |||
| 04 August | +62 | |||
| 03 August | +3 | |||
| 02 August | +2 | |||
| 01 August | 0 |
Channel Posts
| 2 | ACC 2026 HFpEF .pdf | 6 364 |
| 3 | اختيار مضاد الصفائح في مرضى ال
ACS
النقطة الاولى
كل المرضى بياخذوا اسبرين (ما لم يكن ممنوع)
النقطة التانيه هنضيف واحد من ال
P2Y12 inhibitors
واحد من التلاته
Clopidogrel
Ticagrelor
Prasugrel
لو مريض ازمة قلبية، ACS و هيدخل قسطرة يبقى نضيف ال
Ticagrelor or prasugrel
يفضل عن ال
Clopidogrel
اللي هو البلافكس
ودا مبني على ال
PLATO trial
TRITON-TIMI 38 trial
اذا كان واحد من الاتنين مش متاح او ممنوع يتم استخدام البلافكس
مريض ال STEMI اللي بياخد مذيب بياخد في الاساس بلافكس (مش بريليك)
#cardionotes | 2 506 |
| 4 | Thromboembolism prophylaxis (e.g. with
LMWH) is recommended in acute HF patients not already anticoagulated and with no contraindication to anticoagulation.
#cardionotes | 1 973 |
| 5 | لو استخدمت
Triple antithrombotic therapy or dual antithrombotic therapy
وفيهم NOAC
اللي ممكن تقلل جرعته هو ال
Rivaroxaban or dabigatran
For both TAT and DAT regimens, the recommended doses for the NOACs are as follows: Apixaban 5 mg b.i.d., Dabigatran 110 mg or 150 mg b.i.d., Edoxaban
60 mg o.d., Rivaroxaban 15 mg or 20 mg o.d.
#cardionotes | 1 901 |
| 6 | Diabetes mellitus
Chronic kidney disease
Systemic lupus erythematosus
Rheumatoid arthritis
Hypothyroidism
دول اشهر الامراض اللي بترفع الدهون الثلاثية
#cardionotes | 1 757 |
| 7 | β-blockers, preferably non-selective β-blockers (nadolol or propranolol), are recommended in patients with Long QT Syndrome (LQTS) and documented QT interval prolongation to reduce the risk of arrhythmic events.
#cardionotes | 1 478 |
| 8 |  No text... | 1 249 |
| 9 | The maximal daily dose for i.v. loop diuretics is generally considered to be:
* Furosemide: 400–600 mg/day (i.v.)
* Up to 1000 mg/day may be considered in patients with severely impaired kidney function.
#cardionotes | 1 238 |
| 10 | When AV surgery is indicated
Concomitant replacement of the aortic root or ascending aorta should be considered if the maximal diameter is ≥45 mm and the predicted surgical risk is low.
#cardionotes | 1 191 |
| 11 | In acute HF
Inotropes are administered under electrocardiographic monitoring and for a limited period of time due to their detrimental effects including myocardial ischaemia and arrhythmogenesis.In patients pre- treated with beta blockers, levosimendan or milrinone are the preferable inotropes, but in patients with systolic blood pressure below 85 mmHg, both agents should be avoided or used in combination with other inotropes or a vasopressor due to their hypotensive effects.
#cardionotes | 962 |
| 12 | Warfarin acts as a vitamin K antagonist (VKA) by inhibiting vitamin K epoxide reductase, thereby impairing the regeneration of active vitamin K and preventing γ-carboxylation of clotting factors II, VII, IX, and X, as well as proteins C and S.
#cardionotes | 759 |
| 13 | DOAC use in hepatic impairment
Child-Pugh class A: All DOACs appear to be safe.
Child-Pugh class B: Apixaban, dabigatran, and edoxaban can be used, and rivaroxaban should be avoided.
Child-Pugh class C: There is insufficient evidence to support the use of DOACs.
#cardionotes | 730 |
| 14 | All beta- blockers used for treatment of HF are lipophilic, with extensive liver metabolism. Lipid solubility allows these compounds to reside longer and at higher concentrations in cell membranes.
#cardionotes | 850 |
| 15 | الاسبرين يقي من تكرار ال VTE لكن بفاعلية اقل بكتير من ال
DOACs
Low-dose aspirin monotherapy provides modest benefit for secondary prevention of recurrent VTE after completion of anticoagulation, reducing recurrence risk by approximately 30% to 40%; however, it is substantially less effective than extended anticoagulation with DOACs.
#cardionotes | 889 |
| 16 | For most patients with acute VTE planned to receive a DOAC, apixaban should be considered as the treatment of choice
Source: 2026 ACC Scientific Statement; Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events.
#cardionotes | 657 |
| 17 | حالتين من ال
Pulmonary embolism
ممكن يتعالجوا في البيت (دون حجز بالمستشفى)
Subclinical PE
Symptomatic PE with a low clinical severity score.
#cardionotes | 652 |
| 18 |  No text... | 629 |
| 19 | مريض ال VTE اللي هياخذ NOAC
بيستخدم هيبارين
(UFH or LMWH)
لمدة ٥ ايام على الاقل لو هياخد
Dabigatran or edoxaban
اما لو هياخذ واحد من ال
Rivaroxaban or apixaban
فمش محتاج يبدا بهيبارين
بياخذ جرعة عالية في الاول ثم يكمل على الجرعة المعتادة كما بالصورة
والجرعات وال strategies دي بتعتمد على ال
Trials design
اللي اختبرت هذه الادوية في هذه الحالات
في الايام الاولى من تكون الجلطة والعلاج بيكون فيه
Higher risk of recurrence
#cardionotes | 618 |
| 20 | ال
Diltiazem
لا يستخدم اثناء الحمل او الرضاعة
اما ال verapamil ممكن تستخدم
#cardionotes | 556 |
